| Ytd | -38.32% | |
| 1y | -16.37% |
| Open | 9.24 | Prev Close | 9.14 | Low | 9.24 | High | 9.61 | Mkt Cap | 377.94M |
| Vol | 421.97K | Avg Vol | 391.52K | EPS | -1.50 | P/E | N/A | Forward P/E | -1733.00 |
| Beta | 1.05 | Short Ratio | 3.89 | Inst. Own | 92.27% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 10.67 | 200-d Avg | 13.26 | 1yr Est | 24.40 |
OFIX News
Orthofix (OFIX) was a big mover last session on higher-than-average trading volume. The latest trend
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and
Get the latest analyst rating changes for top companies on Wall Street, including upgrades and downg
Barrington Research analyst Michael Petusky maintains Orthofix Medical (NASDAQ:OFIX) with a Outpe
Stifel analyst Thomas Stephan maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the
The Company will highlight these advances at the Pediatric Orthopedic Society of North America (POSN
Orthofix Medical (NASDAQ:OFIX) affirms FY2026 sales outlook from $850.000 million-$860.000 million t
Orthofix Medical (NASDAQ:OFIX) reported quarterly losses of $(0.13) per share which beat the analyst
Company Reports Preliminary First Quarter 2026 Net Sales and Reaffirms 2026 OutlookOrthofix Medical
Stifel analyst Thomas Stephan maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and
Orthofix Medical (NASDAQ:OFIX) sees FY2026 sales of $850.000 million-$860.000 million vs $862.758 mi
Orthofix Medical (NASDAQ:OFIX) reported quarterly earnings of $0.24 per share which beat the analyst
Barrington Research analyst Michael Petusky maintains Orthofix Medical (NASDAQ:OFIX) with a Outpe
TD Cowen analyst Mathew Blackman initiates coverage on Orthofix Medical (NASDAQ:OFIX) with a Hold
Barrington Research analyst Michael Petusky maintains Orthofix Medical (NASDAQ:OFIX) with a Outpe
Orthofix Medical (NASDAQ:OFIX) narrows FY2025 sales outlook from $808.000 million-$816.000 million t
Orthofix Medical (NASDAQ:OFIX) reported quarterly earnings of $0.20 per share which beat the analyst
Stifel analyst Thomas Stephan reinstates Orthofix Medical (NASDAQ:OFIX) with a Buy and announces
Barrington Research analyst Michael Petusky maintains Orthofix Medical (NASDAQ:OFIX) with a Outpe
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and a
Orthofix Medical (NASDAQ:OFIX) affirms FY2025 sales outlook from $808.000 million-$816.000 million t
Orthofix Medical (NASDAQ:OFIX) reported quarterly earnings of $0.13 per share which beat the analyst
Barrington Research analyst Michael Petusky initiates coverage on Orthofix Medical (NASDAQ:OFIX)
JMP Securities analyst David Turkaly reiterates Orthofix Medical (NASDAQ:OFIX) from Market Perfor
Orthofix Medical (NASDAQ:OFIX) lowers FY2025 sales outlook from $818.00 million-$826.00 million to $
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and
Roth MKM analyst Jason Wittes reiterates Orthofix Medical (NASDAQ:OFIX) with a Buy and maintains
Orthofix Medical (NASDAQ:OFIX) sees FY2025 sales of $818.000 million-$826.000 million vs $847.01 mil
Orthofix Medical (NASDAQ:OFIX) reported quarterly earnings of $0.02 per share which beat the analyst
Canaccord Genuity initiates coverage on Orthofix Medical with a Buy rating and $24 price target, cit
Canaccord Genuity analyst Caitlin Burrows initiates coverage on Orthofix Medical (NASDAQ:OFIX) wi
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.